Levonorgestrel subdermal implants. Contraception on trial

Drug Safety

Volumn 17, Issue 6, 1997, Pages 360-368

  Frank, Margaret L ^a   DiMaria, Carrie ^a  

^a UNIVERSITY OF NEW HAVEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; LEVONORGESTREL;

ACNE; ANXIETY NEUROSIS; BLEEDING; BRAIN PSEUDOTUMOR; BREAST CANCER; CLINICAL TRIAL; DEPRESSION; DRUG ABUSE; DRUG CAPSULE; DRUG COST; DRUG IMPLANT; DRUG RESEARCH; FEMALE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; INSURANCE; INTRADERMAL DRUG ADMINISTRATION; INTRAUTERINE CONTRACEPTIVE DEVICE; LAW SUIT; LIVER DISEASE; LIVER TUMOR; OBESITY; PREGNANCY; PRIORITY JOURNAL; PROFIT; REVIEW; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOEMBOLISM; THROMBOPHLEBITIS;

EID: 0031445022     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717060-00002     Document Type: Review

References (62)

1. Segal S. A new delivery system for contraceptive steroids. Am J Obstet Gynecol 1987; 157: 1090-2
2. Gehlert S, Lickey S. Social and health policy concerns raised by the introduction of the contraceptive Norplant. Soc Serv Rev 1995; 69 (2): 323-37
3. Wysowski DK, Green L. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch spontaneous reporting system. Obstet Gynecol 1995; 85: 538-42
4. King EA, Stabler CM, Lien WJ. Pap smear compliance among Norplant users [letter]. J Fam Pract 1995; 41 (1): 16
5. Population group demands halt of Norplant sales: cites health risks to women and targeting of minority populations. PR Newswire 1996 Jun 27: 1
6. Tyrer LB, Salas JE. Contraceptive problems unique to the United States. Clin Obstet Gynecol 1989; 32 (2): 307-15
7. Hataska H. Implantable levonorgestrel contraception: 4 years experience with Norplant. Clin Obstet Gynecol 1995; 38 (4): 859-71
8. Choice and challenge: global teamwork in developing a contraceptive implant. Ontario: International Development Research Centre, 1990
9. Pre-introductory clinical trials of Norplant Implants: a comparison of seventeen countries experience Contraception 1995; 52: 287-96
10. Peers T, Stevens JE, Grahm J, et al. Norplant implants in the UK: first year continuation and removals. Contraception 1996; 53: 345-51
11. Ollila E, Hemminiki E. Does licensing of drugs in industrialized countries guarantee drug quality and safety for third world countries? The case of Norplant licensing in Finland. Int J Health Serv 1997; 27 (2): 309-28
12. Krueger SL, Dunson TR, Amatya RN. Norplant contraceptive acceptability among women in five Asian countries. Contraception 1994; 50: 349-61
13. Brown GF, Moskowitz EH. Moral and policy issues in long-acting contraception. Annu Rev Public Health 1997; 18: 379-400
14. Ollila E, Hemminiki E, Kajesalo K. Physicians' experiences with Norplant implantable contraceptives in Finland. Scand J Soc Med 1995; 23 (1): 47-52
15. Sivin I. Contraception with Norplant implants. Hum Reprod 1994; 9: 1818-26
16. Ollila E, Sihvo S, Meriläinen J, et al. Experience of Finnish women with Norplant insertions and removals. Br J Obstet Gynaecol 1997; 104: 488-94
17. Rosenthal SL, Biro FM, Kollar LM, et al. Experience with side effects and health risks associated with Norplant implant use in adolescents. Contraception 1995; 52: 283-5
18. Levine AS, Holmes MM, Haseldon C, et al. Subdermal contraceptive implant (Norplant) continuation rates among adolescents and adults in a family planning clinic. J Pediatr Adolesc Gynecol 1996; 9 (2): 67-70
19. Phemister DA, Laurent S, Harrison FNH. Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance. Am J Obstet Gynaecol 1995; 172: 175-9
20. Darney PD, Atkinson E, Tanner ST, et al. Acceptance and perceptions of Norplant among users in San Francisco, USA. Stud Fam Plann 1990; 21: 152-60
21. Frank ML, Poindexter AN, Cornin LM, et al. One-year experience with subdermal contraceptive implants in the United States. Contraception 1993; 48: 229-43
22. Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs. oral pills) - an Indian experience. Contraception 1945; 51 (3): 155-65
23. Alvarez-Sanchez F, Brache V, Thevenin F, et al. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol 1996; 174: 919-22
24. Diaz S, Croxatto HB, Pavez M, et al. Clinical assessment of treatments for prolonged bleeding in users of Norplant implants. Contraception 1990; 42: 97-109
25. Kaunitz AM. Long-acting contraceptive options. Int J Fertil 1996; 41 (2): 69-76
26. Chez RA. Serious adverse events in Norplant users related to the Food and Drug Administration's MedWatch spontaneous reporting system [letter]. Obstet Gynecol 1995; 86: 154-5
27. Sivin I. Serious adverse events in Norplant users related to the Food and Drug Administration's MedWatch spontaneous reporting system [letter]. Obstet Gynecol 1995; 86: 318-20
28. Fraser JL, Millenson M, Malynn ER, et al. Possible association between the Norplant contraceptive system and thrombotic thrombocytopenic purpura. Obstet Gynecol 1996; 87: 860-3
29. Wagner KD, Berenson AB. Norplant-associated major depression and panic disorder. J Clin Psychiatry 1994; 55: 478-80
30. Wagner KD. Major depression and anxiety disorders associated with Norplanl. J Clin Psychiatry 1996; 57: 152-7
31. Klavon S, Grubb GS. Insertion site complications during the first year of Norplant use. Contraception 1990; 41: 27-37
32. Su-Juan G, Ming-Lun D, Ling-De Z, et al. A 5-year evaluation of Norplant contraceptive implants in China. Obstet Gynecol 1994; 83: 673-8
33. Zuber TJ, DeWitt DE, Patton DD. Skin damage associated with the Norplant contraceptive. J Fam Pract 1992; 34: 613-16
34. Sivin I. International experience with Norplant and Norplant-2 contraceptives. Stud Fam Plann 1988; 19: 81-94
35. Dunson TR, Amatya RN, Krueger SL. Complications and risk factors associated with the removal of Norplant implants. Obstet Gynecol 1995; 85: 543-8
36. Peers T, Stevens JE, Graham J, Davey A. Norplant implants in the UK: first year continuation and removals. Contraception 1996; 53: 345-51
37. Sarma SP, Hatcher R. The Emory method: a modified approach to Norplant implants removal. Contraception 1994; 49: 551-6
38. Praptohardjo U, Wibowo S. The 'U' technique: a new method for Norplant implants removal. Contraception 1993; 48: 526-36
39. Dunson TR, Amatya RN, Krueger SL. Complications and risk factors associated with the removal of Norplant implants. Obstet Gynecol 1995; 85: 543-48
40. Thomas AG, LeMelle SM. The Norplant system: where are we in 1995? J Fam Pract 1995; 40 (2): 125-8
41. Reynolds RD. The 'Modified U' technique: a refined method of Norplant removal. J Fam Pract 1995; 40: 173-80
42. Cecil H, Holtz JK. Norplant removal facilitated by use of ultrasound for location. J Fam Pract 1995; 40: 182-3
43. Ward SJ, Sidi IPS, Simmons R, et al. Service delivery systems and quality of care in the implementation of Norplant in Indonesia. New York: Population Council, April 1990
44. Hunt L. Shot in the arm for birth control. The Independent 1993 Aug 4: 1
45. Rush for five-year contraceptive. Daily Mail 1993 Oct 8: 11
46. Cullins VE, Blumenthal PD, Remsburg RE, et al. Preliminary experience with Norplant in inner city population. Contraception 1993; 47: 193-203
47. Frank ML, Bateman L, Poindexter AN. The attitudes of clinic staff as factors in women's selection of Norplant implants for their contraception. Women Health 1994; 21 (4): 75-88
48. Doyle C. Doctors set to issue new contraceptive that can last five years. The Daily Telegraph 1993 Aug 5: 4
49. UBINIG. Norplant, the five year needle: an investigation of the Norplant trial in Bangladesh from the user's perspective. Issues Reprod Genet Eng 1990; 3 (3): 211-28
50. UBINIG. "The price of Norplant is TK.20001 You cannot remove it." Clients are refused removal in Norplant trial in Bangladesh. Issues Reprod Genet Eng 1991; 4 (1): 45-6
51. Samuels SE, Smith MD, editors. Dimensions in contraception: Norplant and poor women. Menlo Park. CA: Henry J. Kaiser Family Foundation, 1992
52. Thompson MS. Contraceptive implants: long acting and provider dependent contraception raises concerns about freedom of choice. BMJ 1996; 313 (7069): 1393-5
53. Bromham DR. Contraceptive implants: users lose out when misleading information limits choice. BMJ 1996; 312 (7046): 1555
54. People v. Johnson. No. 29390. Court Proceedings of Tulore County, California, USA
55. Moskowitz EH, Jennings B, Callahan D. Long-acting contraceptives: ethical guidance for policy makers and health care providers. Hastings Center Report 1995; 25 (1) Suppl.: S1-8
56. Kolata G. Will the lawyers kill off Norplant? The New York Times 1995 May 28: Section 3: 1
57. Bromham DR, Davey A, Gaffikin L, et al. Materials, methods and results of the Norplant training program. Adv Contracept 1995; 11: 255-62
58. Jenkins L. Women sue over birth control implant. The Times 1995 Aug 19: 1
59. Glazer SH. Once hailed as 'dream' contraceptive, Norplant faces ethical and practical problems. CQ Researcher 1994; 28 (4): 662-8
60. Mastroianni L, Donaldson PJ, Kane TT. Special report: development of contraceptives - obstacles and opportunities. N Engl J Med 1990; 322 (7): 482-4
61. Sihvo S, Ollila E, Hemminki E. Perceptions and satisfaction among Norplant users in Finland. Acta Obstet Gynecol Scand 1995; 74 (6): 441-5
62. Bromham DR. Contraceptive implants: users lose out when misleading information limits choice. BMJ 1996; 312 (7046): 1555